Skip to main navigation Skip to search Skip to main content

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

  • ARIA study team
  • , ARIA study team

Research output: Contribution to journal › Article › peer-review

107   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases